- ISPOR Latin America Summit 2019
ISPOR Latin America 2019
- Exhibits & Sponsorship
ISPOR Europe 2019
- Abstract Submission
- Short Courses
- Exhibits & Sponsorship
ISPOR Summit 2019
- ISPOR 2019
- ISPOR Warsaw 2019
- ISPOR Europe 2018
- ISPOR Summit 2018
- ISPOR Dubai 2018
- ISPOR Asia Pacific 2018
- ISPOR 2018
- ISPOR Europe 2017
- ISPOR Latin America 2017
- ISPOR Asia Pacific 2016
- Submit Abstract
- Exhibits & Sponsorships
- Awards & Grants
- Upcoming Conferences
Education & Training
- In-Person Training
- Introduction to Outcomes Research
- Introduction to Systematic Reviews & Meta-Analysis
- Systematic Review & Meta-Analysis: Applications
- Introduction to Pharmacoeconomics
- Cost-of-Illness/Cost-Estimation (COI/CE)
- Cost-Minimization/Cost-Consequence (CMA/CCA)
- Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA)
- Modeling Health Care Costs – Part I: Characteristics of Health Care Costs
- Modeling Health Care Costs – Part II: Methods and Guidelines for Estimating Health Care Costs
- Modeling Health Care Costs – Part III: Estimation from Censored Data
- Introduction to Budget Impact Analysis (BIA) - Part I
- Introduction to Budget Impact Analysis (BIA) - Part II
- Markov Model Toolkit: Concepts, Assumptions and Examples
- An Introduction to Choice-Based Conjoint Analysis (Discrete Choice Experiments)
- Health-Related Quality of Life (HRQOL) – Basics
- Patient Reported Outcomes: Analysis and Interpretation
- Patient Reported Outcomes: Instrument Development
- Item Response Theory: A Conceptual Introduction
- Preparing for Multinational Clinical Trials: Translation and Cultural Adaptations of PRO Measures
- Evidence Generation for Patient Reported Outcome (PRO) Label Claims (FDA Requirements)
- Intermediate Retrospective Observational Study - Propensity Scoring Methods
- Use of Public Survey Data in Health Outcomes Research
- Using RWE to Improve Healthcare Decision-making in Asia Pacific
- Top 10 HEOR Trends of 2019
- The Use of MCDA for HTA Agencies
- MCDA - How to Guide of Different Methods for Assessment of Rare Disease HT
- Virtualizing Long-Term Follow-Up Studies for Gene Therapy Products
- Is the FDA's New Guidance a Watershed Moment for Real-world Evidence?
- Topics in Evaluating the Cost-Effectiveness of Gene Therapies
- Distance Learning
This module is an introduction to the role of cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) in medical decision making from multiple perspectives. It will describe situations in which CEA is the acceptable method of pharmacoeconomic (PE) analysis, the components included, computational methods, cost composition, effectiveness metrics [e.g., life-years saved (LYS) quality-adjusted life-years, new thrombosis avoided]; incremental vs. average cost-effectiveness ratios; primary and intermediate clinical outcomes; sensitivity analysis; absolute vs. relative values and use of CEA and CUA in medical decision making.
By the end of the Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA) module, you will be able to:
- State the role of cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) in medical decision making.
- Define the components of CEA and CUA.
- Understand the computations involved in CEA and CUA.
- Understand the concerns in attribution of cost components to a particular treatment arm.
- Summarize the resources used in a therapy or service and assign monetary values to those resources.
- Explain the use of applications such as Microsoft Excel and DATA™ to develop and perform CEAs and CUAs.
- Analyze the value for money from health technologies
- Compare and contrast different cost-utility models of human papillomavirus (HPV) vaccine, using five published HPV vaccine cost-utility models as the basis for medical decision making.
- Summarize how CEA and CUA are used in health policy decisions regarding government approval of and reimbursement for therapies.
- Use and apply sensitivity analyses and discounting techniques in CEA and CUA.
- Explain how point of view and perspective affect CEA and CUA.